Echo Therapeutics Symphony® tCGM System To Be Profiled on The Doctors Television Show

Published on Tuesday, 08 May 2012 09:01 Written by TradersHuddle Staff

PHILADELPHIA, May 8, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that CEO, Patrick T. Mooney, M.D. will appear on the Wednesday, May 9th airing of the popular Emmy Award-winning television show The Doctors.

Dr. Mooney discusses the benefits of the Symphony tCGM System with The Doctors co-host, Dr. Travis Stork.  Local listings for The Doctors can be found at www.thedoctorstv.com.

"We are thrilled to have our continuous glucose monitoring technology profiled on The Doctors," stated Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics.  "Building on the positive momentum we have generated with the results of our recent clinical trial, we are excited to increase the visibility of our needle-free Symphony tCGM System."

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:

Christine H. Olimpio 

Director, Investor Relations and Corporate Communications

(215) 717-4104                                                                   

Connect With Us:

- Visit our website at www.echotx.com

- Follow us on Twitter at www.twitter.com/echotx

- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.